Status: Not yet recruiting
ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1
The goal of this clinical trial is to learn if ASTX727 can be combined with retifanlimab to treat Merkel cell cancer. It will also learn about the safety of combining these drugs. The main questions it aims to answer are: * Can the combination shrink cancer and lower the chance of the cancer growing or spreading? * Is the combination better than standard of care for Merkel cell cancer? Participants will: * Take oral ASTX727 and retifanlimab through a vein in the arm for about 2 years. * Visit the clinic once every 2 weeks for checkups and tests
Participants needed: 31
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of Wisconsin, MadisonUpdated: Jul 1, 2026Locations: 1
Eligibility criteria
Individuals age ≥ 18 years at the time of consent [+5]
Prior treatment with a hypomethylating agent (HMA) (e.g., azacitidine, decitabin... [+4]